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Background: Māori men in New Zealand have higher mortality from prostate cancer, despite having lower
incidence rates. The objective of this study was to examine patterns of screening for prostate cancer in primary care
and follow-up investigations after an elevated prostate-specific antigen (PSA) result in Māori and non-Māori men in
order to help explain the observed differences in incidence and mortality.
Methods: Men aged 40+ years were identified from 31 general practices across the Midland Cancer Network
region. Computerised practice records were cross-referenced with laboratory data to determine the number and
value of PSA tests undertaken between January 2007 and December 2010. Screening rates were calculated for the
year 2010 by age, ethnicity, and practice. For men with an elevated PSA result information on specialist referrals
and biopsy was extracted from practice records. Practice characteristics were assessed with respect to screening
rates for Māori and non-Māori men.
Results: The final study population included 34,960 men aged 40+ years; 14% were Māori. Māori men were less
likely to be screened in 2010 compared with non-Māori men (Mantel Haenszel (M-H) age-adjusted risk ratio (RR),
0.52 [95% CI, 0.48, 0.56]). When screened, Māori men were more than twice as likely to have an elevated PSA result
compared with non-Māori men (M-H age-adjusted RR, 2.16 [95% CI, 1.42, 3.31]). There were no significant
differences between Māori and non-Māori men in the rate of follow-up investigations and cancer detection. Māori
provider practices showed equal screening rates for Māori and non-Māori men, but they were also the practices
with the lowest overall screening rates.
Conclusions: Māori men were half as likely to be screened compared to non-Māori men. This probably explains
the lower reported incidence of prostate cancer for Māori men. Practice characteristics had a major influence on
screening rates. Large variation in screening behaviour among practices and differences in follow-up investigations
for men with an elevated PSA result seems to reflect the uncertainty among GPs regarding PSA screening and
management.
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Prostate cancer has been identified as the primary con-
tributor to cancer burden in New Zealand men; with
prostate cancer burden for Māori men being 50% higher
compared with non-Māori men [1]. Māori men were re-
ported to have higher mortality from prostate cancer,
despite having lower incidence rates [2-4].
Although screening for prostate cancer is not recom-
mended in New Zealand due to the controversy about
its harms versus benefits [5-7], it is common in New
Zealand general practice [8,9]. Screening rates in New
Zealand are similar to other countries with privatised
primary care services, such as the USA, Canada and
Australia [10-12]. In 2010, approximately 80% of prostate-
specific antigen (PSA) tests were undertaken in asymp-
tomatic men [13], which means that by definition they
were screening tests [14]. Despite the limitations of the
PSA test when used as a screening tool, it is currently
considered to be the best single test for early detection
of prostate cancer [15].
A significant proportion of general practitioners (GPs)
in New Zealand believes that screening for prostate cancer
is beneficial [13,16]. A recent study has found that 80% of
PSA testing in New Zealand primary care was initiated by
GPs, not by patients [13]. Similar screening behaviour and
beliefs have been reported from other countries [17-19].
In the USA, differences in screening practices, such as
availability and interval of screening contribute to ethnic
disparities in prostate cancer incidence and mortality
[20]. It is unclear whether the low prostate cancer inci-
dence and high mortality for Māori men are due to dis-
parities in screening or biopsy rates, resulting in later
tumour stage at diagnosis for Māori men, and/or over-
detection of indolent cancers for non-Māori men.
An in-depth understanding of the patterns of PSA
screening in primary care is needed in order to explain
the differences in prostate cancer incidence and mortal-
ity between Māori and non-Māori men in New Zealand
so that evidence-based interventions can be developed
to eliminate unfair and avoidable inequities.
The aim of this study was to ascertain annual PSA
screening rates for Māori and non-Māori men using
computerised records from general practices linked with
laboratory data. Men with elevated PSA result were
followed-up to examine management pathways, includ-
ing referral and biopsy rates by ethnicity. The influence
of practice characteristics on difference in screening rates
between Māori and non-Māori men was also explored.
Methods
Study population
A cohort of men aged 40+ years enrolled in 31 general
practices in the Midland Cancer Network (MCN) region
was identified from computerised practice records. Eachgeneral practice provided baseline data (National Health
Index code, date of birth, ethnicity) on all male patients
aged 40+ years enrolled with the practice in 2010. Prac-
tices were purposefully selected to ensure sufficient num-
bers of Māori men and geographical coverage of the MCN
region, which covers three District Health Boards (DHBs)
of Waikato, Bay of Plenty and Lakes. There were approxi-
mately 150 general practices in the MCN region at the
time of research.
Data sources
All practices used the Healthtech Medtech software for
recording patient data, clinical notes, and laboratory
results. Men with a PSA test in 2010 were identified by
cross-referencing data from the computerised practice
records with laboratory data. Data linkage was based
on the National Health Index (NHI) code, a unique identi-
fier for people using health services in New Zealand.
All PSA results for the period from 1 January 2007 to
31 December 2010 were obtained from three community
laboratories serving the MCN region; with more than
90% of tests being undertaken in one laboratory (Pathlab).
Data on prostate cancer registrations for the years 1994
to 2011 were available from the New Zealand Cancer
Registry (NZCR). The NZCR collects data on all new cases
of malignant cancers excluding squamous cell carcinoma
and basal cell carcinoma of the skin. By linking the NHI
numbers of the NZCR and the practice records, 1,006
men, of whom 69 were Māori (6.9%) with a prostate can-
cer diagnosis prior to 1 January 2010 or prior to any PSA
test in 2010 were identified. These men were excluded
from further analyses.
Outcome variables
In order to calculate screening rates for prostate cancer,
all men with a PSA test between 1 January 2010 and 31
December 2010 were identified. In men with more than
one PSA test during 2010, the earliest test result was
considered in the analysis. When one of the test results
(not necessarily the earliest one) was elevated, the man
was categorised as having an elevated PSA test during
2010. PSA values were classified as being elevated
when they exceeded age-specific levels adapted from
Oesterling et al. [21], as used by the local laboratories
(40-49 years: >2.5 ng/ml; 50-59 years: >3.5 ng/ml; 60-
69 years: >4.5 ng/ml; 70-79 years: >6.5 ng/ml; 80+
years: >7.0 ng/ml).
Men were classified as being screened when they had
no elevated PSA result or prostate biopsy in the three
years prior to 2010. In addition, men with elevated PSA
result in 2010 were considered to be screened when
there was no record of symptoms (urinary tract symp-
toms, erectile dysfunction, bone pain) for that year in
the computerised practice records.
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up investigations, including specialist referral and biopsy
were extracted. The NHI codes of men with elevated
PSA result were also cross-referenced with pathology re-
ports made available by the laboratories to ascertain data
completeness regarding whether biopsy was undertaken,
and what the result was. Men were followed up until 31
December 2011.
Predictor variables
Ethnicity was extracted from general practice records.
Patients who enrol with a general practice in New
Zealand are asked to report their ethnicity along with
other personal information. Men were categorised as
either Māori or non-Māori. In the latter group, 91.9%
were European, 2.4% Pacific, 3.3% Asian, and 2.4% of
other ethnicity. Patients’ age was grouped into four
categories (40-69, 60-69, 70-79 and 80+ years) for the
assessment of screening rates. Age was collapsed into
two categories (-40-59 years, 70+ years) for assessing
the rates of follow-up investigations.
Individual practices were categorised by several parame-
ters: Practices governed by Māori organisations were la-
belled Māori provider practices and were compared to
other (not Māori provider) provider practices. Māori pro-
vider practices offer primary health care services rooted in
Māori cultural practices, customs and world view.
Māori provider practices were then compared to other
provider practices with respect to their size, including
number of men aged 40+ years enrolled in the practice
(<500 versus 500+), and number of GPs in the practice
(1-3 versus 4+), and the proportion of Māori men aged
40+ years (<20% versus 20%+). In addition, practices were
categorised by screening rate (<20% versus 20% + screened
men aged 40+ years).
Statistical analysis
Statistical analysis was performed with SPSS 19.0 and
STATA IC/12 and included the Mantel-Haenszel (M-H)Figure 1 Age distribution in Midland Cancer Network (MCN) region aage-adjusted risk ratios (RR) calculated to compare
screening rates, rates of elevated PSA results, follow-up
investigations and cancer detection for Māori and non-
Māori men. Mantel-Haenszel (M-H) age-adjusted risk
ratios (RR) for Māori compared to non-Māori men were
also calculated by practice.
Access to computerised records of general practices
was obtained through close cooperation with general
practitioners and practice managers. Ethical approval
was issued by the Northern Y Ethics Committee (NTY/
11/02/019). Māori consultation included the Midland
Cancer Network Māori Advisory Group Hei Pa Harakeke,
and Te Puna Oranga, the Waikato District Health Board
Māori Unit.
Results
Screening rates and follow-up investigations
The preferential sampling of practices with high Māori
population has proven successful as shown by compar-
ing the demographic characteristics of this cohort with
those of the MCN male population aged 40+ years. In
2010, there were 36,740 men enrolled in the 31 general
practices, accounting for 25% of the estimated total male
population aged 40+ years in the MCN region in 2010
[22]. Māori men comprised 14.3% (4986) of the final
cohort. The estimated proportion of Māori men aged
40+ years residing in the MCN region in 2010 was
14.4% [22]. The age structure of Māori and non-Māori
men of this cohort was similar to that of the total male
population aged 40+ years in the MCN region (Figure 1).
The final study population included 34,960 men aged
40+ years after men diagnosed with prostate cancer before
2010 (1006) and men with unknown ethnicity (774) were
excluded. Table 1 shows cohort characteristics of Māori
and non-Māori men from 31 general practices.
Māori men were younger than non-Māori men, which
is consistent with the age structure differences between
total Māori and non-Māori population in New Zealand
[23]. Māori men were less likely to have a PSA test innd our cohort by ethnicity.
Table 1 Characteristics of the cohort of Māori and
non-Māori men from 31 general practices
Māori Non-Māori
(N = 4986) (N = 29974)
n % n %
Age
40-59 years 3749 75.2 17874 59.6
60-69 years 805 16.1 6613 22.1
70-79 years 374 7.5 3814 12.7
80+ years 58 1.2 1673 5.6
PSA test in 2010 650 13.0 8066 26.9
PSA test between 2007 and 2009
(% of tested men)
303 46.6 5092 63.1
PSA level (% of tested men)
0-3.99 ng/ml 554 85.2 6824 84.6
4-9.99 ng/ml 71 10.9 976 12.1
10-19.99 ng/ml 18 2.8 189 2.3
20+ ng/ml 7 1.1 77 1.0
Table 3 Frequency of follow-up investigations and
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the three years prior to 2010 compared with non-Māori
men.
The screening rate for Māori men was 11.2% com-
pared with 22.6% for non-Māori men, thus Māori men
were 48% less likely to be screened compared with non-
Māori men (M-H age-adjusted RR, 0.52 [95% CI, 0.48,
0.56]; Table 2). When screened, 168 men had an elevated
PSA result. There were 4.3% of Māori men and 2.1% of
non-Māori men with an elevated PSA result (M-H age-
adjusted RR, 2.16 [95% CI, 1.42, 3.31]; Table 2).Table 2 Screening rates in 2010 and proportion of men
with elevated PSA result by age and ethnicity
Screening in 2010 Men with elevated PSA
result ()
n (%) n (% of screened men)
Māori Non-Māori Māori Non-Māori
40-59 yrs 350 3385 12 52
(9.3) (18.9) (3.4) (1.5)
60-69 yrs 146 2095 7 64
(18.1) (31.7) (4.8) (3.1)
70-79 yrs 55 1055 5 21
(14.7) (27.7) (9.1) (2.0)
80 + yrs 6 251 0 7
(10.3) (15.0) (0) (2.8)
Total 557 6786 24 144
(11.2) (22.6) (4.3) (2.1)
Mantel-Haenszel
age-adjusted RR
0.52 [0.48, 0.56] 2.16 [1.42, 3.31]
[95% CI]In total, 66 (39.3%) men were referred after an elevated
PSA result and 44 (66.7%) had a biopsy following referral.
Of the men who underwent a biopsy, 27 (61.4%) were
found to have cancer. Table 3 summarises age-specific re-
ferral, biopsy rates and results for Māori and non-Māori
men. There were no significant differences between Māori
and non-Māori men in the rates of follow-up investiga-
tions and cancer detection (Table 3). Cancer detection
rate from men at risk (with elevated PSA result) was
167 per 1000 for Māori men and 160 per 1000 for non-
Māori men. Cancer detection rate from all screened
men was 7 per 1000 for Māori men and 3 per 1000 for
non-Māori men.
Practice characteristics and disparities in screening rates
Māori provider practices were predominantly smaller
with respect to the number of enrolled men aged 40+
years, and to the number of general practitioners in the
practice compared with other provider practices. In each
of the Māori provider practices, Māori men represented
20 +% (ranging from 22% to 75%) of the enrolled men,
while only one-fourth of the other providers had 20 +%
of Māori men in their practice (the proportion ranged
from 4% to 35%). Only one of the Māori provider practices
(12.5%) was characterised as high-screening (with an over-
all screening rate of 20+ %) compared with 13 (59.6%) of
the other provider practices.
The age-adjusted RR for Māori men being screened
(compared with non-Māori men) by practice characterised
by the overall proportion of screened men is depictedprostate cancer diagnosis in screened men with an
elevated PSA result by age and ethnicity
Māori Non-Māori
Referral
(% of men with elevated PSA result)
n/N (%) n/N (%)
40-69 years 9/19 (47.4%) 44/116 (37.9%)
70+ years 2/5 (40.0%) 11/28 (39.3%)
Total 11/24 (45.8%) 55/144 (38.2%)
Mantel-Haenszel adjusted RR [95% CI] 1.2 [0.74, 1.94]
Biopsy (% of referred men)
40-69 years 6/9 (66.7%) 33/44 (75.0%)
70+ years 1/2 (50.0%) 4/11 (36.4%)
Total 7/11 (63.6%) 37/55 (67.3%)
Mantel-Haenszel adjusted RR [95% CI] 0.94 [0.58, 1.50]
Positive biopsy
(% of men with biopsy)
40-69 years 3/6 (50.0%) 19/33 (57.6%)
70+ years 1/1 (100%) 4/4 (100%)
Total 4/7 (57.1%) 23/37 (62.2%)
Mantel-Haenszel adjusted RR [95% CI] 0.90 [0.46, 1.73]
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ing rates among practices (4.8% to 34.8%). There were
two practices that had a RR of Māori and non-Māori
screening rates close to (0.97) or above 1 (1.36), both of
which were Māori provider practices (Figure 2).
In Māori provider practices Māori men were 34% less
likely to be screened compared with non-Māori men
(M-H age-adjusted RR, 0.66 [95% CI, 0.51, 0.85]), while
in other practices Māori men were 45% less likely to be
screened compared with non-Māori men (M-H age-
adjusted RR, 0.55 [95% CI, 0.50, 0.60]).
Discussion
Māori men were half as likely to be screened for prostate
cancer compared with their non-Māori peers. Lower
screening rates have been commonly associated with
lower prostate cancer incidence rates [11,20,24,25]. Several
New Zealand studies have pointed out that incidence rates
for prostate cancer are lower in Māori men compared
with non-Māori men [26-28]. Our population-based study
is the first to show that lower PSA screening rates are a
significant factor contributing to lower prostate cancer
incidence rates for Māori men.
Only 2% of screened men had an elevated PSA, so an
overwhelming majority was shown to have a normal
PSA result. However, screened Māori men were twice as
likely to have an elevated PSA result compared with
non-Māori men. This finding may be partly due to the
fact that Māori men were less likely to have been tested
in the three years prior to 2010, implying that there is a
greater potential for detecting prostate issues in Māori
men compared with more frequently tested non-Māori
men.
There were no significant differences in the rates of
follow-up investigations and cancer detection betweenFigure 2 Risk ratio of Māori men being screened by practice characteMāori and non-Māori men with an elevated PSA result.
In general, 39% of men with an elevated PSA result were
referred to a specialist in the follow-up period, meaning
that the majority of these men were managed in general
practice. One of the reasons why general practitioners
(GPs) do not immediately refer men with elevated PSA
result may be their awareness of the fact that an increase
in PSA level can be caused by prostatic diseases other
than prostate cancer, such as prostatitis and benign
prostatic hyperplasia [29,30]. GPs may feel that repeated
PSA tests are needed to assess the actual risk of prostate
cancer before referring to a specialist.
Overall, 67% of referred men went on to have a biopsy.
It is recommended that the decision when to proceed to
prostate biopsy should be primarily based on PSA level
and the result of digital rectal examination, but other
factors, including patient’s age, family history, and co-
morbidities may be considered by the specialist [6,31].
These factors may also influence GPs’ decision to refer
for a specialist assessment in the first place.
In our study, there was a large variation between prac-
tices in PSA screening rates. This finding is consistent
with studies from other countries [32-34]. It has been
shown that besides patient characteristics, such as age
and co-morbidities, GP and practice characteristics, in-
cluding the number of GPs in the practices and the
number of patients seen by the GP influence screening
behaviour [17,35-37]. In addition, studies on screening
behaviour of physicians report that GPs believe in the
benefits of PSA screening, which is probably one of the
reasons why they commonly initiate it [13,17,35]. It has
also been shown that GPs expressed difficulties in under-
standing and explaining to patients the complexities of
screening for prostate cancer [13,17,38]. Such difficulties
have been attributed to the lack of consensus in screeningrised by proportion of men aged 40+ years screened in 2010.
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as internationally [18,39]. For example, at the time of
our research the Urological Society of Australia and
New Zealand [40] has recommended that asymptomatic
men aged 55-69 years should be offered a prostate-specific
antigen (PSA) test and digital rectal examination (DRE)
after the patients have been advised on the risks and
benefits of PSA screening, while in contrast, the Ministry
of Health (The National Screening Advisory Committee)
has not supported population-based screening for prostate
cancer [7].
In the vast majority of practices Māori men were less
likely to be screened, however, two Māori provider prac-
tices showed relatively equal screening rates for Māori
and non-Māori men. Concurrently, Māori provider prac-
tices showed the lowest overall screening rates among
the 31 practices. Māori provider practices differed from
other provider practices with respect to a higher propor-
tion of Māori patients but they were also smaller in terms
of both number of patients and GPs. With the knowledge
that screening is mainly GP-driven, it is unclear why GPs
are less likely to initiate prostate cancer screening for
Māori men. More research is needed into reasons for the
50% lower screening rates for Māori versus non-Māori
men in New Zealand.
Strengths and limitations
The strength of this study is that population-based data
were acquired from the general practice computerised
records, which allowed us to distinguish the reasons for
PSA testing, and thus calculate rates for screening com-
pared with testing due to symptoms or disease monitor-
ing. In addition, we were able to link the practice-based
records through unique NHI numbers to laboratory data
and prostate cancer registrations, meaning that we could
cross-validate information from practices and acquire
comprehensive history on PSA testing and follow-up care,
including specialist referrals and biopsy results. One of the
main advantages of this study was sufficient numbers of
Māori men for statistical evaluation of the results.
We identified four potential limitations to our study:
Firstly, practice notes might not be complete, particu-
larly regarding reasons for PSA testing. Secondly, we
did not record information on symptoms for men with-
out an elevated PSA; we estimated the proportion of
screened men based on information about elevated
PSA tests or biopsies prior to 2010. Therefore, the
overall number of screened men may be overestimated.
In a pilot study based on data from five general prac-
tices in the Midland Cancer Network region examining
reasons for testing in all men with PSA test in 2010,
11% of men were tested due to symptoms, and the pro-
portion of screened men was 75% compared with 85%
in our study [13].Thirdly, we have considered men enrolled in the
general practices in 2010 as the baseline population,
not men who visited their GP in that year. However, a
current NZ Health Survey showed that more than 80%
of men older than 40 years visited their GP in 2011/
2012 and Māori men were as likely to visit their GPs as
non-Māori men [41].
Fourthly, the sample size was probably not sufficient
for robust analysis of secondary outcomes, i.e. referral
and biopsy rates. However, we believe that the presented
findings will guide further research into the outcomes of
screening for prostate cancer in New Zealand.
Conclusions
This study makes an important contribution to New
Zealand’s national dialogue on prostate cancer inequities
between Māori and non-Māori men, prostate cancer
screening and cancer inequities in general. We found
that lower PSA screening rates in Māori men are a major
determinant of a lower prostate cancer incidence. Due to
potential harms of prostate cancer screening [7], it is not
clear whether Māori men would benefit from increased
screening rates. Māori men were more likely to have an
elevated PSA result compared with non-Māori men,
suggesting that a larger proportion of Māori men was at
risk of prostate cancer compared with non-Māori men.
There was a large variation in PSA screening rates
among practices, with Māori provider practices showing
the lowest overall screening rates. Although there were
no differences between Māori and non-Māori men in
the proportion of follow-up investigations, overall less
than half of the men with an elevated PSA result were
referred to a specialist for further examination. The
large variation in screening patterns among practices
may be partly attributed to inconsistent recommenda-
tions for screening by various organisations, but this
argument would not hold for the observed differences
by ethnicity. One recommendation that has been found
to be consistent for a majority of organisations is that
decisions around screening should be made following
an in-depth discussion about the pros and cons of
screening between the patient and his health care pro-
vider. Screening in New Zealand is currently mainly
GP-driven, so there is obviously a need for more educa-
tion for GPs, probably more discussion time between
GPs and patients around screening and prostate cancer
detection, and for strategies leading to improvements in
health literacy, thereby creating an environment, in which
shared decision-making between GPs and patients can
be achieved.
More research is needed to better understand GP
decision-making about screening pathways for prostate
cancer, which will in turn help to further clarify the
causes of higher mortality rates for Māori compared
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opportunistic screening is relatively common in New
Zealand but varies widely by practice and ethnicity. Bet-
ter understanding of prostate cancer risk on an individ-
ual basis, employing shared decision-making regarding
screening and consistent follow-up strategies for men
considered to be at higher risk of prostate cancer may
help to target resources and thus improve outcomes,
particularly for Māori men in the future. The ultimate
goal should be to devise strategies for prostate cancer con-
trol that unite best practice, equity, and cost-effectiveness
of health care services.
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